Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor
	Acts as a drug target

Gene: JUN

Summary for JUN

Gene information	Gene symbol	JUN
	Ensembl ID	ENSG00000177606
	Entrez ID	3725
	Gene name	Jun proto-oncogene, AP-1 transcription factor subunit
	Synonyms	AP-1\|c-Jun
	Gene type	protein_coding
	UniProtAcc	P05412

Top

Dataset with differentially expressed gene: JUN

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	1.32527	2.19e-05
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	-0.342192	1.04e-07
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	-0.300205	6.28e-30
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.665934	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	0.341343	1.88e-05
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.975496	5.25e-08
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.406216	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.447652	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.714106	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	0.882533	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.64261	3.03e-07
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.89649	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.868042	1.25e-43
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	pDCs	1.27685	1.62e-02
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	1.07154	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.827767	8.15e-37
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.625285	1.72e-06
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.715252	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.97902	0.00e+00
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-1.17369	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	-0.764278	3.65e-32
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	-0.827019	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	-0.419294	4.35e-40
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD4+ T cells	0.436812	1.64e-11
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	Mono/Macro	0.86271	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	cDCs	0.844204	1.97e-09
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD4+ T cells	-0.987522	7.95e-27
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	-1.26748	9.78e-16
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-0.719985	1.82e-38
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-2.06769	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-1.17403	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	0.259914	3.63e-26
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	CD4+ T cells	0.435921	0.00e+00
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	-0.507535	1.69e-24
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.330071	4.64e-03
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.465108	2.39e-12
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	NK cells	-0.4863	6.59e-44
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD4+ T cells	-0.296793	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	-0.571892	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD8+ T cells	-0.533228	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD4+ T cells	-0.327504	5.59e-43
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	0.79133	1.53e-06
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	-0.339789	5.28e-09
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	1.63026	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	-0.62677	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.582745	2.23e-05
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	B cells	0.580299	3.91e-13
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD4+ T cells	0.265643	1.92e-17
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.574417	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	0.78377	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	cDCs	0.916584	1.61e-02
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	2.33748	3.74e-26
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	0.976374	4.06e-29
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	1.44995	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	0.283089	1.54e-15
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-1.19378	1.21e-32
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-1.4142	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Mono/Macro	-0.469649	2.14e-13
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD4+ T cells	-0.808316	1.03e-03
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-0.921476	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	0.536071	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	0.524546	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	1.47443	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.33016	3.17e-39
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.473035	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.339785	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.594662	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.674216	9.53e-15
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.555661	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	0.291758	3.32e-02
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	Malignant cells	-0.720492	4.68e-26
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	-0.752751	4.80e-27
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	-0.71141	2.83e-20
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD4+ T cells	-1.1134	4.10e-14
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	-0.943978	4.68e-23
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Malignant cells	-1.31326	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	NK cells	-1.07085	3.34e-04
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	Malignant cells	0.725595	0.00e+00
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.403292	8.42e-12
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.400437	1.45e-05
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	0.489186	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	NK cells	-0.69305	6.74e-29
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD8+ T cells	-0.74562	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD4+ T cells	-0.458072	3.13e-03
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD4+ T cells	-0.702327	4.44e-14
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	-1.66485	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	B cells	-0.831398	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD8+ T cells	-0.917457	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	1.53962	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	cDCs	-0.632496	1.63e-02
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Mono/Macro	-0.638419	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	1.306	0.00e+00

Top

Expression of JUN in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to JUN

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Gene symbol	Mechanism
JUN	Unusual Activation of Pro-survival Pathway

Page: 1

Top

MicroRNAs (miRNA) regulating JUN

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
JUN	hsa-miR-139-5p	98.2733	NM_002228
JUN	hsa-miR-524-5p	95.7471	NM_002228
JUN	hsa-miR-520d-5p	95.7471	NM_002228
JUN	hsa-miR-501-5p	94.9656	NM_002228
JUN	hsa-miR-200c-3p	93.8338	NM_002228
JUN	hsa-miR-429	93.8338	NM_002228
JUN	hsa-miR-200b-3p	93.8338	NM_002228
JUN	hsa-miR-4803	92.5938	NM_002228
JUN	hsa-miR-493-5p	85.4688	NM_002228
JUN	hsa-miR-4533	85.2195	NM_002228
JUN	hsa-miR-495-3p	84.354	NM_002228
JUN	hsa-miR-5688	84.354	NM_002228
JUN	hsa-miR-8084	83.4823	NM_002228
JUN	hsa-miR-4504	82.3841	NM_002228
JUN	hsa-miR-4693-3p	81.7524	NM_002228

Page: 1

Top

Motifs and transcription factors (TFs) regulating JUN

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
JUN	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	ETS2 (directAnnotation).
JUN	cisbp__M02645	ETS1 (directAnnotation).
JUN	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	GMEB1 (directAnnotation).
JUN	cisbp__M08198	ELF1 (directAnnotation).
JUN	dbtfbs__E2F8_representative_N1	E2F8 (directAnnotation).
JUN	transfac_pro__M04950	EGR1 (directAnnotation).
JUN	taipale_cyt_meth__E2F2_GCGCGCGCGYW_eDBD_repr	E2F2 (directAnnotation).
JUN	taipale_tf_pairs__E2F1_ELK1_SGCGCNNNNNCGGAAGN_CAP_repr	E2F1; ELK1 (directAnnotation).
JUN	taipale_tf_pairs__E2F1_HES7_RRCRCGYGYNNNNSGCGCSN_CAP_repr	E2F1; HES7 (directAnnotation).
JUN	transfac_pro__M04866	HDAC2 (directAnnotation).
JUN	metacluster_34.1	ZNF143; ZNF143; ZNF143; ZNF76; ZNF76; ZNF76 (directAnnotation).
JUN	kznf__ZNF594_Schmitges2016_RCADE	ZNF594 (directAnnotation).
JUN	hocomoco__KLF13_HUMAN.H11MO.0.D	KLF13 (directAnnotation).
JUN	taipale_cyt_meth__E2F2_NCGCGCGCGCM_eDBD_meth	E2F2 (directAnnotation).
JUN	transfac_pro__M07387	ZBTB7A (directAnnotation).
JUN	transfac_pro__M07436	WT1 (directAnnotation).
JUN	transfac_pro__M07461	KLF1; KLF10; KLF11; KLF12; KLF13; KLF15; KLF16; KLF17; KLF2; KLF3; KLF4; KLF5; KLF6; KLF7; KLF8; KLF9 (directAnnotation).
JUN	transfac_pro__M00716	ZBTB14 (directAnnotation).
JUN	swissregulon__hs__CHD1	CHD1 (directAnnotation).
JUN	hdpi__HIP2	UBE2K (directAnnotation).
JUN	taipale_tf_pairs__GCM1_SPDEF_RTGNKGGCGGAWG_CAP_repr	GCM1; SPDEF (directAnnotation).
JUN	transfac_pro__M04893	TAF1 (directAnnotation).
JUN	transfac_pro__M03876	ZBTB33 (directAnnotation).
JUN	metacluster_133.1	ZNF304; ZNF304; ZSCAN22 (directAnnotation).
JUN	transfac_pro__M01219	SP1 (directAnnotation). SP3 (inferredBy_Orthology).
JUN	metacluster_3.7	SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP3; SP3; SP3; SP4; SP4; SP4; SP4; SP4; SP4; SP5 (directAnnotation).
JUN	transfac_pro__M02015	FOXA3 (directAnnotation).
JUN	transfac_pro__M06917	ZNF236 (directAnnotation).
JUN	metacluster_111.4	ATF1; ATF1; ATF1; ATF1; ATF1; ATF1; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF3; ATF3; ATF3; ATF3; ATF3; ATF4; ATF4; ATF5; ATF6; ATF6B; ATF7; ATF7; ATF7; BATF3; BATF3; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB3; CREB3L4; CREB3L4; CREB5; CREB5; CREB5; CREM; CREM; CREM; CREM; CREM; FOSB; FOSL1; FOSL1; FOSL2; JDP2; JDP2; JDP2; JUN; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; XBP1; XBP1; XBP1; ZNF629 (directAnnotation). ATF1; ATF1; ATF1; ATF2; ATF2; ATF3; ATF6; ATF6B; ATF7; ATF7; ATF7; ATF7-NPFF; ATF7-NPFF; ATF7-NPFF; ATF7-NPFF; BATF; BATF2; BATF3; CREB1; CREB1; CREB3; CREB3L1; CREB3L2; CREB3L3; CREB3L4; CREM; FOS; FOSB; FOSL1; FOSL2; JDP2; JDP2 (inferredBy_Orthology).
JUN	taipale_tf_pairs__FOXJ2_HOXB13_TTTWATNRNMAACA_CAP_repr	FOXJ2; HOXB13 (directAnnotation).
JUN	transfac_pro__M07447	CARF (directAnnotation).
JUN	homer__TWVGGTCCGC_HINFP	HINFP (directAnnotation).
JUN	transfac_pro__M04817	ZBTB33 (directAnnotation).
JUN	transfac_pro__M00803	E2F1; E2F3; E2F4; TFDP1 (directAnnotation).
JUN	tfdimers__MD00546	HOXC8; NFE2L1 (directAnnotation).
JUN	transfac_pro__M06363	ZNF730 (directAnnotation).
JUN	transfac_pro__M12441	ZNF281 (inferredBy_Orthology).
JUN	tfdimers__MD00432	DBP; STAT1 (directAnnotation).
JUN	taipale_cyt_meth__ZNF385D_NCGTCGCGACGN_eDBD_repr	ZNF385D (directAnnotation).
JUN	taipale_tf_pairs__TEAD4_DLX2_RGWATGYTAATKR_CAP_repr	DLX2; TEAD4 (directAnnotation).
JUN	metacluster_180.3	ATF2; ATF2; ATF2; ATF2; ATF3; ATF3; ATF4; ATF4; ATF6; ATF6B; ATF7; ATF7; BACH2; BATF3; BATF3; CREB1; CREB1; CREB3; FOSL1; FOSL2; JDP2; JUN; JUN; JUN; JUND; JUND; XBP1; ZBTB21 (directAnnotation). JDP2; JDP2; JUND (inferredBy_Orthology).
JUN	taipale_tf_pairs__PBX4_HOXA10_CCATAAATCA_CAP	HOXA10; PBX4 (directAnnotation).
JUN	transfac_public__M00039	CREB1 (directAnnotation).
JUN	transfac_pro__M05785	ZNF48 (inferredBy_Orthology).
JUN	taipale_tf_pairs__TEAD4_ERG_RSCGGAAATRCC_CAP	ERG; TEAD4 (directAnnotation).
JUN	metacluster_23.5	WT1 (directAnnotation).
JUN	transfac_public__M00114	CREB1 (directAnnotation).
JUN	metacluster_131.3	ZNF436 (inferredBy_Orthology).
JUN	metacluster_52.13	LEF1; LEF1; LEF1; LEF1; TCF7; TCF7; TCF7L1; TCF7L1 (directAnnotation).
JUN	taipale_tf_pairs__GCM1_ETV4_RTGCGGGCGGAAGTR_CAP	ETV4; GCM1 (directAnnotation).

Page: 1 2 3 4 5 6 7

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

TF	motif	Expression	Cell type	Dataset	Timepoint
JUN	tfdimers__MD00475	down	CD8+ T cells	GSE111014	post
JUN	metacluster_157.2	down	CD4+ T cells	GSE111014	pre
JUN	cisbp__M01816	down	Malignant cells	GSE111014	pre
JUN	tfdimers__MD00165	down	NK cells	GSE111014	pre
JUN	tfdimers__MD00230	down	NK cells	GSE111014	pre
JUN	metacluster_137.2	down	Malignant cells	GSE131984_Pac	NA
JUN	transfac_pro__M04879	down	Malignant cells	GSE131984_Pac	NA
JUN	taipale_tf_pairs__JUN_ATGACGTCAT_HT	down	Malignant cells	GSE131984_Pac	NA
JUN	metacluster_58.7	up	Malignant cells	GSE152469	NA
JUN	metacluster_111.4	up	Malignant cells	GSE152469	NA
JUN	metacluster_111.4	down	CD8+ T cells	GSE161801_IMiD	post
JUN	metacluster_137.2	down	CD8+ T cells	GSE161801_IMiD	post
JUN	metacluster_180.3	down	CD8+ T cells	GSE161801_IMiD	post
JUN	metacluster_111.4	down	B cells	GSE161801_IMiD	pre
JUN	metacluster_58.7	down	CD4+ T cells	GSE161801_IMiD	pre
JUN	metacluster_50.1	down	CD4+ T cells	GSE161801_IMiD	pre
JUN	metacluster_180.3	down	CD8+ T cells	GSE161801_IMiD	pre
JUN	taipale_tf_pairs__JUN_ATGACGTCAT_HT	down	CD8+ T cells	GSE161801_IMiD	pre
JUN	metacluster_58.7	down	cDCs	GSE161801_IMiD	pre
JUN	metacluster_137.2	down	NK cells	GSE161801_IMiD	pre
JUN	metacluster_157.2	down	NK cells	GSE161801_IMiD	pre
JUN	taipale_tf_pairs__JUN_ATGACGTCAT_HT	down	NK cells	GSE161801_IMiD	pre
JUN	taipale_tf_pairs__JUN_ATGACGTCAT_HT	up	CD8+ T cells	GSE161801_PI	post
JUN	metacluster_111.4	up	CD8+ T cells	GSE161801_PI	post
JUN	metacluster_180.3	up	CD8+ T cells	GSE161801_PI	post
JUN	metacluster_148.1	up	CD8+ T cells	GSE161801_PI	post
JUN	transfac_public__M00041	up	CD8+ T cells	GSE161801_PI	post
JUN	metacluster_111.4	up	cDCs	GSE161801_PI	post
JUN	metacluster_157.2	up	NK cells	GSE161801_PI	post
JUN	tfdimers__MD00141	up	NK cells	GSE161801_PI	post
JUN	transfac_pro__M02280	up	NK cells	GSE161801_PI	post
JUN	metacluster_50.1	up	NK cells	GSE161801_PI	post
JUN	metacluster_180.3	up	NK cells	GSE161801_PI	post
JUN	transfac_public__M00041	down	CD4+ T cells	GSE161801_PI	pre
JUN	tfdimers__MD00475	down	CD4+ T cells	GSE161801_PI	pre
JUN	taipale_tf_pairs__JUN_ATGACGTCAT_HT	down	CD4+ T cells	GSE161801_PI	pre
JUN	metacluster_157.2	up	CD8+ T cells	GSE161801_PI	pre
JUN	metacluster_137.2	up	CD8+ T cells	GSE161801_PI	pre
JUN	metacluster_50.1	up	CD8+ T cells	GSE161801_PI	pre
JUN	cisbp__M01816	down	Malignant cells	GSE161801_PI	pre
JUN	tfdimers__MD00586	down	Mono/Macro	GSE161801_PI	pre
JUN	tfdimers__MD00141	down	NK cells	GSE161801_PI	pre
JUN	metacluster_157.2	up	cDCs	GSE162117	post
JUN	metacluster_157.2	down	Mono/Macro	GSE164551	NA
JUN	metacluster_137.2	down	Mono/Macro	GSE164551	NA
JUN	metacluster_111.4	down	B cells	GSE169246_PacAteTissue	pre
JUN	metacluster_157.2	down	CD8+ T cells	GSE169246_PacAteTissue	pre
JUN	tfdimers__MD00165	down	NK cells	GSE169246_PacAteTissue	pre
JUN	tfdimers__MD00165	down	Mono/Macro	GSE169246_PacBlood	post
JUN	metacluster_157.2	down	Mono/Macro	GSE169246_PacBlood	post

Page: 1 2 3

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
JUN	"Adapalene"	DB00210	small molecule
JUN	"Arsenic trioxide"	DB01169	small molecule
JUN	"Irbesartan"	DB01029	small molecule
JUN	"LGD-1550"	DB05785	small molecule
JUN	"Vinblastine"	DB00570	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."